Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

After Novo Nordisk A/S' (NYSE:NVO) launch of the first oral GLP-1 weight-loss drug, the spotlight at the JPMorgan Healthcare Conference turned sharply toward obesity treatments and what comes next for the rapidly expanding market.

Citing an interview at the conference, CNBC on Wednesday said Ray Stevens, CEO of Structure Therapeutics Inc (NASDAQ:GPCR), outlined how his company plans to position itself as a key contender as oral therapies gain traction.

Stevens said the coming year will be pivotal as Structure prepares to advance its daily oral GLP-1 candidate, aleniglipron, into Phase 3 trials.

He expects recently approved and upcoming pills from Novo Nordisk and Eli Lilly and Co. (NYSE:LLY) to see strong ...